Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder

Psychopharmacology

Volumn 232, Issue 20, 2015, Pages 3833-3840

  Hunter, Aimee M ^a,b   Cook, Ian A ^a,b,c   Tartter, Molly ^d   Sharma, Simi K ^a   Disse, Gregory D ^a   Leuchter, Andrew F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Engineering IV   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant medication; Antidepressant treatment history; Expectations; Placebo response; Randomized clinical trial; Tachyphylaxis; Tolerance; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; PLACEBO; VENLAFAXINE;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; MIXED EFFECTS MODELS WITH REPEATED MEASURES ANALYSIS; MORNING DOSAGE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PLACEBO EFFECT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; TREATMENT DURATION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PSYCHOLOGY; STANDARDS;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SELF REPORT;

EID: 84941268865     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-4047-2     Document Type: Article

References (30)

1. Amsterdam JD, Maislin G, Potter L (1994) Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 18(2):243-261
2. Amsterdam JD, Shults J (2005) MAOI efficacy and safety in advanced stage treatment-resistant depression: a retrospective study. J Affect Disord 89(1-3):183-188
3. Amsterdam JD, Williams D, Michelson D, Adler LA, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF (2009) Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 59(4):227-233
4. Brown WA, Johnson MF, Chen MG (1992) Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 41(3):203-214
5. Cohen J (1988) Statistical power analysis for the behavioral sciences. Mahwah, New Jersey, pp 283-286
6. Fava GA, Offidani E (2011) The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 35:1593-1602
7. Fountoulakis KN, Gonda X, Andreoulakis E, Fokas K, Iacovides A (2013) No differences between drug naive and drug experienced unipolar depressed patients in terms of neurobiological testing: a cross sectional study. J Psychiatr Res 47(12):1984-1990
8. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303(1):47-53
9. Hamilton M (1960) A rating scale for depression. J Neurol Neursurg Psychiatr 23:56-62
10. Hunter AM, Cook IA, Abrams M, Leuchter AF (2013) Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes? Med Hypotheses 81(6):1004-1011
11. Hunter AM, Cook IA, Leuchter AF (2010) Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. J Clin Psychopharmacol 6:748-751
12. Hunter AM, Cook IA, Leuchter AF (2012) Does prior antidepressant treatment of major depression impact brain function during current treatment? Eur Neuropsychopharmacol 22(10):711-720
13. Khan A, Bhat A, Kolts R, Thase ME, Brown W (2010) Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 16(4):217-226
14. Khan A, Leventhal RM, Khan SR, Brown WA (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40-45
15. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5(2), e45
16. Leuchter AF, Cook IA, Hunter AM, Korb AS (2009) A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci 11(4):435-446
17. Leuchter AF, Hunter AM, Tartter M, Cook IA (2014) Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry 205(6):443-449
18. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD (2007) Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 75(2):267-276
19. Peselow ED, Sanfilipo MP, Difiglia C, Fieve RR (1992) Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 149:1324-1334
20. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe W, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD Report. Am J Psychiatry 163:1905-1917
21. Rutherford BR, Marcus SM, Wang P, Sneed JR, Pelton G, Devanand D, Duan N, Roose SP (2013) A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med 43(5):975-982
22. Rutherford BR, Roose SP (2013) A model of placebo response in antidepressant clinical trials. Am J Psychiatry 170(7):723-733
23. Rutherford BR, Wall M, Glass A, Stewart JW (2014) The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry 75(10):1040-1046
24. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33
25. Simon GE, Rutter CM, Stewart C et al (2012) Response to past depression treatments is not accurately recalled: comparison of structured recall and patient health questionnaire scores in medical records. J Clin Psychiatry 73(12):1503-1508
26. Ten Have TR, Normand ST, Marcus SM, Brown CH, Lavori P, Duan N (2008) Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatr Ann 38(12):772-783
27. Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287(14):1840-1847
28. Weimer K, Colloca L, Enck P (2015) Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2(3):246-257
29. Weiss M, Gaston L, Propst A, Wisebord S, Zicherman V (1997) The role of the alliance in the pharmacologic treatment of depression. J Clin Psychiatry 58(5):196-204
30. Young AM, Goudie AJ (1995) Adaptive processes regulating tolerance to behavioral effects of drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: 4th generation of progress. Raven, New York, pp 733-742